|
Name |
Hydrouracil, 1-methyl-
|
Molecular Formula | C5H8N2O2 | |
IUPAC Name* |
1-methyl-1,3-diazinane-2,4-dione
|
|
SMILES |
CN1CCC(=O)NC1=O
|
|
InChI |
InChI=1S/C5H8N2O2/c1-7-3-2-4(8)6-5(7)9/h2-3H2,1H3,(H,6,8,9)
|
|
InChIKey |
LPQUIFIUJKZJRT-UHFFFAOYSA-N
|
|
Synonyms |
Hydrouracil, 1-methyl-; 696-11-7; 1-methyl-1,3-diazinane-2,4-dione; 1-methyldihydropyrimidine-2,4(1h,3h)-dione; methyldihydrouracil; NSC42057; 1-methyl-5,6-dihydrouracil; 2,4(1H,3H)-Pyrimidinedione, dihydro-1-methyl-; SCHEMBL3182138; DTXSID40285495; ZINC160407; MFCD00127872; NSC-42057; 1-methylhexahydropyrimidine-2,4-dione; AKOS004910242; SB56872; BS-38449; 2,3H)-Pyrimidinedione, dihydro-1-methyl-; CS-0230251; EN300-102933; 1-Methyldihydro-2,4(1H,3H)-pyrimidinedione #; Z852405042
|
|
CAS | 696-11-7 | |
PubChem CID | 237963 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 128.13 | ALogp: | -1.0 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 49.4 | Aromatic Rings: | 1 |
Heavy Atoms: | 9 | QED Weighted: | 0.499 |
Caco-2 Permeability: | -4.712 | MDCK Permeability: | 0.00001650 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.072 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.043 |
Blood-Brain-Barrier Penetration (BBB): | 0.998 | Plasma Protein Binding (PPB): | 8.83% |
Volume Distribution (VD): | 0.707 | Fu: | 76.10% |
CYP1A2-inhibitor: | 0.023 | CYP1A2-substrate: | 0.579 |
CYP2C19-inhibitor: | 0.037 | CYP2C19-substrate: | 0.27 |
CYP2C9-inhibitor: | 0.029 | CYP2C9-substrate: | 0.615 |
CYP2D6-inhibitor: | 0.016 | CYP2D6-substrate: | 0.477 |
CYP3A4-inhibitor: | 0.005 | CYP3A4-substrate: | 0.184 |
Clearance (CL): | 6.828 | Half-life (T1/2): | 0.872 |
hERG Blockers: | 0.015 | Human Hepatotoxicity (H-HT): | 0.05 |
Drug-inuced Liver Injury (DILI): | 0.215 | AMES Toxicity: | 0.02 |
Rat Oral Acute Toxicity: | 0.058 | Maximum Recommended Daily Dose: | 0.058 |
Skin Sensitization: | 0.381 | Carcinogencity: | 0.014 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.318 |
Respiratory Toxicity: | 0.014 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000393 | 0.433 | D0K8IX | 0.303 | ||||
ENC002258 | 0.267 | D0Q4XQ | 0.282 | ||||
ENC001820 | 0.267 | D00ETS | 0.273 | ||||
ENC004743 | 0.267 | D0WB9V | 0.263 | ||||
ENC003583 | 0.265 | D0Z9NZ | 0.255 | ||||
ENC000751 | 0.263 | D02OZY | 0.250 | ||||
ENC005486 | 0.263 | D0M6DO | 0.246 | ||||
ENC000882 | 0.250 | D0U4VT | 0.225 | ||||
ENC000991 | 0.250 | D0R0BX | 0.224 | ||||
ENC005207 | 0.240 | D0Q5NX | 0.222 |